Astellas is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting a “Focus Area Approach” that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. We are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions combining our expertise and knowledge with cutting-edge technology in different fields of external partners. With over 25 years of dedication in support of the advancement of care for transplant patients, we continue to build upon our legacy of providing innovative life-saving and life-changing immunosuppressant therapies for patients undergoing transplantation for patients around the world. Through all these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.
CareDx, Inc. is committed to improving transplant patient outcomes by providing innovative and intelligent solutions throughout the entire patient journey. We are a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.
Hansa Biopharma is a biopharmaceutical company based in Lund, Sweden and also has operations in other European countries and in the U.S. It is developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. In Europe, the European Commission has recently granted conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Learn how we applied our expertise of over 2 million cfDNA tests performed by quantifying background cfDNA to refine risk of rejection in your transplant patients.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.
Transplant Genomics (“TGI”) is a transplant diagnostics company committed to bringing personalized diagnostics to transplant patients worldwide. Working with the transplant community, TGI has developed TruGraf®, the only blood test validated and reimbursed to rule out “silent” subclinical acute rejection in kidney transplant recipients with stable graft function.
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit www.viracor-eurofins.com.